\-\ Texto\\:\\ \ \(0\)\
\-\ follow\\-up\\ ct\\ chest\\ in\\ one\\ year\\ to\\ ensure\\ stability\\ or\\ improvement\\.\ \(0\)\
\-\ ct\\ remarkable\\ for\\:\ \(0\)\
\-\ mediastinum\\:\\ noncalcified\\ mediastinal\\ and\\ bilateral\\ hilar\\ lymphadenopathy\\.\\ no\\ cardiac\\ enlargement\\.\\ no\\ pericardial\\ effusion\\.\\ \ \(0\)\
\-\ lungs\\:\\ in\\ the\\ right\\ upper\\ lobe\\ there\\ is\\ a\\ patchy\\ and\\ confluent\\ ground\\-glass\\ density\\ 4\\.6\\ x\\ 3\\.3cm\\ \\(image\\ 27\\)\\ and\\ peribronchovascular\\ interstitial\\ thickening\\ that\\ can\\ be\\ traced\\ from\\ this\\ density\\ to\\ the\\ hila\\ \\(see\\ image\\ 32\\)\\.\\ in\\ both\\ upper\\ and\\ right\\ middle\\ lobes\\ there\\ are\\ areas\\ of\\ ground\\ glass\\ opacity\\ with\\ a\\ peribronchial\\ vascular\\ distribution\\.\ \(0\)\
\-\ chest\\ radiograph\\ remarkable\\ for\\ prominent\\ bilateral\\ hila\\.\ \(0\)\
\-\ sarcoidosis\ \(108\)\
\-\ sarcoidosis\ \(108\)\
\-\ bronchalveolar\\ cell\\ carcinoma\ \(0\)\
\-\ infectious\\,\\ fungal\\ or\\ mycobacterial\ \(0\)\
\-\ lymphoma\\ or\\ malignancy\\ \\(4\\)\ \(0\)\
\-\ langerhans\\ cell\\ histiocytosis\\ \ \(0\)\
\-\ hypersensitivity\\ pneumonitis\ \(9\)\
\-\ lymphangitic\\ carcinomatosis\ \(14\)\
\-\ pneumoconiosis\ \(7\)\
\-\ 46\\ year\\ old\\ female\\ presents\\ for\\ follow\\ up\\ ct\\.\\ relatively\\ asymptomatic\\.\ \(0\)\
\-\ discussion\\:\ \(1\)\
\-\ \\ \\ \\ \\ \\ \\ \\ \\ the\\ patient\\ came\\ to\\ us\\ with\\ a\\ well\\ established\\ diagnosis\\ of\\ sarcoidosis\\ since\\ 1998\\ \\(8\\ years\\)\\.\\ \\ the\\ patient\\ was\\ followed\\ with\\ chest\\ radiographs\\ until\\ she\\ presented\\ 2\\ years\\ ago\\ with\\ a\\ ct\\ order\\ for\\ \\‚\\Ä\\úseveral\\ abnormal\\ cts\\‚\\Ä\\ù\\ from\\ an\\ outside\\ institution\\.\\ ct\\ with\\ contrast\\ at\\ that\\ time\\ was\\ consistent\\ with\\ stage\\ ii\\ sarcoidosis\\ with\\ enlarged\\ mediastinal\\ and\\ bilateral\\ hilar\\ lymph\\ nodes\\ and\\ areas\\ of\\ parenchymal\\ abnormality\\ with\\ the\\ additional\\ finding\\ suggestive\\ of\\ a\\ superimposed\\ infectious\\ process\\ such\\ as\\ non\\-tuberculous\\ mycobacterial\\ infection\\.\\ 2\\ years\\ ago\\,\\ in\\ the\\ patient\\'s\\ ct\\ scan\\,\\ it\\ was\\ noted\\ in\\ the\\ impression\\ that\\ bronchoalveolar\\ carcinoma\\ or\\ foci\\ of\\ atypical\\ adenomatous\\ hyperplasia\\ was\\ part\\ of\\ the\\ differential\\ because\\ of\\ an\\ increase\\ in\\ diameter\\ of\\ a\\ nodule\\ from\\ 5mm\\ to\\ 10mm\\.\\ since\\ that\\ time\\ the\\ patient\\ has\\ been\\ followed\\ clinically\\ and\\ with\\ ct\\.\\ \\ this\\ ct\\ demonstrated\\ no\\ enlargement\\.\ \(0\)\
\-\ \\ \\ \\ \\ \\ \\ \\ \\ the\\ usual\\ indications\\ for\\ lung\\ ct\\ scans\\ are\\ for\\ 1\\)\\ atypical\\ clinical\\ and\\/or\\ chest\\ radiographic\\ findings\\,\\ 2\\)\\ detection\\ of\\ complications\\ of\\ the\\ lung\\ disease\\,\\ such\\ as\\ bronchiectasis\\,\\ aspergilloma\\,\\ pulmonary\\ fibrosis\\,\\ emphysema\\,\\ or\\ a\\ superimposed\\ infection\\ or\\ malignancy\\,\\ 3\\)\\ a\\ normal\\ chest\\ radiograph\\ but\\ a\\ clinical\\ suspicion\\ for\\ sarcoidosis\\ \\(5\\)\\.\\ hrct\\ is\\ not\\ recommended\\ to\\ be\\ performed\\ on\\ all\\ patients\\ with\\ sarcoidosis\\,\\ but\\ it\\ may\\ be\\ helpful\\ for\\ the\\ above\\ reasons\\ and\\ for\\ selected\\ patients\\ with\\ stage\\ ii\\ or\\ iii\\ disease\\ to\\ discriminate\\ active\\ inflammation\\ from\\ irreversible\\ fibrosis\\ \\(5\\)\\.\\ \ \(0\)\
\-\ \\ \\ \\ \\ \\ \\ \\ \\ although\\,\\ langerhans\\ cell\\ histiocytosis\\ shares\\ some\\ ct\\ features\\ with\\ sarcodosis\\;\\ bronchial\\ distortion\\,\\ displaced\\ fissures\\,\\ and\\ perihilar\\ predominance\\ are\\ absent\\ in\\ lch\\ \\(5\\)\\.\\ \\ \ \(0\)\
\-\ \\ \\ \\ \\ \\ \\ \\ \\ with\\ hypersensitivity\\ pneumonia\\,\\ the\\ features\\ of\\ centrilobular\\ nodules\\,\\ a\\ mosaic\\ pattern\\ of\\ attenuation\\ \\(air\\ trapping\\)\\,\\ and\\ peribronchial\\ \\(often\\ confluent\\)\\ ground\\ glass\\ opacities\\ are\\ more\\ common\\ and\\ prominent\\ in\\ acute\\ or\\ subacute\\ hp\\ compared\\ to\\ sarcoidosis\\.\\ subacute\\ and\\ acute\\ phase\\ hp\\ preferentially\\ distributes\\ in\\ the\\ lower\\ lobes\\ \\(5\\)\\.\\ it\\ is\\ suggested\\ to\\ use\\ ct\\ to\\ look\\ for\\ concomittent\\ symmetric\\ hilar\\ and\\ medastinal\\ lymph\\ node\\ enlargement\\ or\\ the\\ presence\\ of\\ reticular\\ nodular\\ opacities\\ elsewhere\\ for\\ diagnostic\\ clues\\ \\(1\\)\\.\\ \\ \ \(0\)\
\-\ \\ \\ \\ \\ \\ \\ \\ \\ both\\ sarcoidosis\\ and\\ lymphangitic\\ carcinomatosis\\ cause\\ a\\ beaded\\ appearance\\ along\\ the\\ bronchovascular\\ bundles\\.\\ lymphangitic\\ carcinomatosis\\ causes\\ a\\ more\\ marked\\ septal\\ thickening\\ with\\ thickened\\ polygonal\\ lines\\,\\ the\\ hallmark\\ of\\ this\\ disease\\.\\ furthermore\\,\\ with\\ sarcoidosis\\,\\ the\\ nodules\\ typically\\ have\\ irregular\\ margins\\ as\\ those\\ in\\ lymphangitic\\ carcinomatosis\\ have\\ smooth\\ margins\\ \\(5\\)\\.\\ silicosis\\ can\\ be\\ mimicked\\ by\\ sarcoidosis\\ with\\ the\\ formation\\ of\\ conglomerate\\ masses\\ of\\ fibrosis\\ in\\ the\\ upper\\ perihilar\\ regions\\ \\(1\\)\\.\ \(0\)\
\-\ sarcoidosis\ \(108\)\
\-\ \\	\\	\ \(94\)\
\-\ definition\\/background\\:\\ sarcoidosis\\ is\\ a\\ multisystem\\ granulomatous\\ disease\\ characterized\\ histologically\\ by\\ noncaseating\\ granulomas\\ \\(1\\)\\.\\ \ \(0\)\
\-\ \\	\ \(2191\)\
\-\ epidemiology\\:\\ sarcoidosis\\ is\\ more\\ common\\ in\\ blacks\\ than\\ whites\\ and\\ it\\ is\\ rare\\ in\\ asians\\ \\(1\\)\\.\\ sarcoidosis\\ shows\\ a\\ predilection\\ for\\ women\\ with\\ most\\ patients\\ being\\ 20\\-40\\ years\\ old\\ at\\ the\\ time\\ of\\ diagnosis\\ \\(1\\,2\\)\\.\\ in\\ the\\ united\\ states\\,\\ the\\ estimated\\ lifetime\\ incidence\\ of\\ sarcoidosis\\ in\\ african\\ americans\\ is\\ 2\\.4\\%\\ versus\\ 0\\.85\\%\\ in\\ whites\\ \\(2\\)\\.\\ \ \(0\)\
\-\ etiology\\:\\ etiology\\ is\\ unknown\\ \\(2\\)\\.\ \(0\)\
\-\ \\	\ \(2191\)\
\-\ pathogenesis\\:\\ activation\\ of\\ pulmonary\\ macrophages\\ that\\ recruit\\ mononuclear\\ cells\\ leading\\ to\\ the\\ formation\\ of\\ granulomas\\ \\(1\\)\\.\\ the\\ granulomas\\ are\\ a\\ discrete\\ tight\\ collection\\ of\\ noncaseating\\ epitheliod\\ cells\\.\\ the\\ early\\ sarcoidosis\\ reaction\\ is\\ characterized\\ by\\ accumulation\\ of\\ cd45ro\\+\\,\\ t\\ lymphocytes\\,\\ and\\ macrophages\\.\\ an\\ unknown\\ stimulus\\ causing\\ persistent\\ inflammation\\ and\\ accumulation\\ of\\ chemoattractant\\ cytokines\\ to\\ an\\ inflamed\\ area\\ are\\ proposed\\ granuloma\\ formation\\ mechanisms\\ \\(2\\)\\.\\ dense\\ bands\\ of\\ fibroblasts\\,\\ mast\\ cells\\,\\ collagen\\,\\ and\\ proteoglycans\\ may\\ encase\\ the\\ granuloma\\ and\\ lead\\ to\\ fibrosis\\ and\\ irreversible\\ destruction\\ of\\ affected\\ organs\\ \\(5\\)\\.\\ \ \(0\)\
\-\ \\	\ \(2191\)\
\-\ clinical\\ presentation\\:\\ lofgren\\‚\\Ä\\ôs\\ syndrome\\ presents\\ in\\ 20\\%\\-50\\%\\ of\\ all\\ cases\\ of\\ acute\\ disease\\.\\ lofgren\\‚\\Ä\\ôs\\ syndrome\\ presents\\ as\\ pulmonary\\ hilar\\ lymphadenopathy\\,\\ polyarthralgias\\,\\ and\\ erythema\\ nodosum\\.\\ 50\\%\\ of\\ patients\\ receive\\ the\\ diagnosis\\ of\\ sarcoidosis\\ after\\ presenting\\ for\\ chronic\\ cough\\,\\ dyspnea\\ or\\ chest\\ pain\\.\\ delay\\ in\\ diagnosis\\ is\\ often\\ due\\ to\\ the\\ non\\-specific\\ mild\\ nature\\ of\\ early\\ symptoms\\,\\ misdiagnosis\\,\\ and\\ economic\\ barriers\\ to\\ medical\\ care\\.\\ african\\ americans\\ are\\ more\\ likely\\ to\\ have\\ extrathoracic\\ involvement\\ of\\ the\\ bone\\ marrow\\,\\ skin\\,\\ liver\\,\\ and\\ eyes\\ \\(uveitis\\)\\ compared\\ to\\ whites\\.\\ whites\\ are\\ more\\ likely\\ to\\ have\\ hypercalcemia\\ \\(2\\)\\.\\ \\ other\\ laboratory\\ findings\\ include\\ hypergammaglobulinemia\\,\\ elevated\\ serum\\ angiotensin\\-converting\\ enzyme\\ and\\ cutaneous\\ anergy\\ to\\ ppd\\ skin\\ test\\ \\(1\\)\\.\\ \ \(0\)\
\-\ findings\\:\\ 90\\%\\ of\\ patients\\ with\\ sarcoidosis\\ show\\ abnormalities\\ on\\ chest\\ radiographs\\.\\ enlargement\\ of\\ the\\ mediastinal\\ and\\ hilar\\ \\.\\.\\.\\.\\.\\.\\.\\(continued\\)\\ see\\ disease\\ topic\\ 7308\ \(0\)\
\-\ Keywords\\ by\\ value\\:\\ \ \(0\)\
\-\ sarcoidosis\\:\\ 0\\.07221875737481734\ \(0\)\
\-\ whites\\:\\ 0\\.027080803870987328\ \(0\)\
\-\ lymphangitic\\:\\ 0\\.023617564274583572\ \(0\)\
\-\ hilar\\:\\ 0\\.022316683196036684\ \(0\)\
\-\ carcinomatosis\\:\\ 0\\.02175467561542781\ \(0\)\
\-\ \\)\\:\\ 0\\.020768248834898695\ \(0\)\
\-\ \\(\\:\\ 0\\.01877239413315646\ \(0\)\
\-\ lofgren\\:\\ 0\\.018327481130907482\ \(0\)\
\-\ granulomas\\:\\ 0\\.017099731539889692\ \(0\)\
\-\ fibrosis\\:\\ 0\\.015820719874720342\ \(0\)\
\-\ 5\\:\\ 0\\.015593516148300396\ \(0\)\
\-\ noncaseating\\:\\ 0\\.01544537227203037\ \(0\)\
\-\ hp\\:\\ 0\\.01498145636493222\ \(0\)\
\-\ chest\\:\\ 0\\.014878485447403982\ \(0\)\
\-\ 1\\:\\ 0\\.01479551411197292\ \(0\)\
\-\ enlargement\\:\\ 0\\.01409799753216256\ \(0\)\
\-\ irreversible\\:\\ 0\\.014004317842591815\ \(0\)\
\-\ americans\\:\\ 0\\.014004317842591815\ \(0\)\
\-\ ct\\:\\ 0\\.013667713292424609\ \(0\)\
\-\ 2\\:\\ 0\\.013389533758392748\ \(0\)\
\-\ hila\\:\\ 0\\.013342251873530412\ \(0\)\
\-\ peribronchial\\:\\ 0\\.013161355039872136\ \(0\)\
\-\ macrophages\\:\\ 0\\.012840875456031683\ \(0\)\
\-\ \\%\\:\\ 0\\.012432355717334767\ \(0\)\
\-\ mycobacterial\\:\\ 0\\.012318392237152462\ \(0\)\
\-\ perihilar\\:\\ 0\\.01209934750605511\ \(0\)\
\-\ hypersensitivity\\:\\ 0\\.011808782137291786\ \(0\)\
\-\ \\:\\:\\ 0\\.011749218461441426\ \(0\)\
\-\ confluent\\:\\ 0\\.011720300610433582\ \(0\)\
\-\ patients\\:\\ 0\\.011494670474875394\ \(0\)\
\-\ superimposed\\:\\ 0\\.011399821026593128\ \(0\)\
\-\ mediastinal\\:\\ 0\\.011314342883968013\ \(0\)\
\-\ more\\:\\ 0\\.011107984975634961\ \(0\)\
\-\ formation\\:\\ 0\\.010999744469663087\ \(0\)\
\-\ cells\\:\\ 0\\.010685384701091469\ \(0\)\
\-\ langerhans\\:\\ 0\\.010507938270837704\ \(0\)\
\-\ years\\:\\ 0\\.010433443397166248\ \(0\)\
\-\ or\\:\\ 0\\.010410839386317126\ \(0\)\
\-\ glass\\:\\ 0\\.010279246180995027\ \(0\)\
\-\ histiocytosis\\:\\ 0\\.009885811670312016\ \(0\)\
\-\ for\\:\\ 0\\.00985281281949615\ \(0\)\
\-\ \\,\\:\\ 0\\.009849118807801517\ \(0\)\
\-\ ground\\:\\ 0\\.009780965820775858\ \(0\)\
\-\ are\\:\\ 0\\.009687100811056979\ \(0\)\
\-\ remarkable\\:\\ 0\\.009648921318234638\ \(0\)\
\-\ accumulation\\:\\ 0\\.00946536080441826\ \(0\)\
\-\ opacities\\:\\ 0\\.009269874422613112\ \(0\)\
\-\ african\\:\\ 0\\.009269874422613112\ \(0\)\
\-\ bronchalveolar\\:\\ 0\\.009163740565453741\ \(0\)\
\-\ shares\\:\\ 0\\.009163740565453741\ \(0\)\
\-\ sarcodosis\\:\\ 0\\.009163740565453741\ \(0\)\
\-\ distributes\\:\\ 0\\.009163740565453741\ \(0\)\
\-\ concomittent\\:\\ 0\\.009163740565453741\ \(0\)\
\-\ medastinal\\:\\ 0\\.009163740565453741\ \(0\)\
\-\ definition\\/background\\:\\ 0\\.009163740565453741\ \(0\)\
\-\ cd45ro\\+\\:\\ 0\\.009163740565453741\ \(0\)\
\-\ chemoattractant\\:\\ 0\\.009163740565453741\ \(0\)\
\-\ proteoglycans\\:\\ 0\\.009163740565453741\ \(0\)\
\-\ polyarthralgias\\:\\ 0\\.009163740565453741\ \(0\)\
\-\ hypergammaglobulinemia\\:\\ 0\\.009163740565453741\ \(0\)\
\-\ angiotensin\\-converting\\:\\ 0\\.009163740565453741\ \(0\)\
\-\ anergy\\:\\ 0\\.009163740565453741\ \(0\)\
\-\ \\.\\.\\.\\.\\.\\.\\.\\:\\ 0\\.009163740565453741\ \(0\)\
\-\ 7308\\:\\ 0\\.009163740565453741\ \(0\)\
\-\ subacute\\:\\ 0\\.009115803794434895\ \(0\)\
\-\ characterized\\:\\ 0\\.00883819175155647\ \(0\)\
\-\ granuloma\\:\\ 0\\.008732635981549353\ \(0\)\
\-\ disease\\:\\ 0\\.008711460756023102\ \(0\)\
\-\ peribronchovascular\\:\\ 0\\.008443213350734464\ \(0\)\
\-\ non\\-tuberculous\\:\\ 0\\.008443213350734464\ \(0\)\
\-\ epitheliod\\:\\ 0\\.008443213350734464\ \(0\)\
\-\ stimulus\\:\\ 0\\.008443213350734464\ \(0\)\
\-\ mast\\:\\ 0\\.008443213350734464\ \(0\)\
\-\ \\-50\\:\\ 0\\.008443213350734464\ \(0\)\
\-\ nodosum\\:\\ 0\\.008443213350734464\ \(0\)\
\-\ clinical\\:\\ 0\\.008199510811016646\ \(0\)\
\-\ diagnosis\\:\\ 0\\.008158916136301122\ \(0\)\
\-\ margins\\:\\ 0\\.008068699565147207\ \(0\)\
\-\ 3\\.3cm\\:\\ 0\\.008021731949374625\ \(0\)\
\-\ discriminate\\:\\ 0\\.008021731949374625\ \(0\)\
\-\ mosaic\\:\\ 0\\.008021731949374625\ \(0\)\
\-\ polygonal\\:\\ 0\\.008021731949374625\ \(0\)\
\-\ conglomerate\\:\\ 0\\.008021731949374625\ \(0\)\
\-\ multisystem\\:\\ 0\\.008021731949374625\ \(0\)\
\-\ asians\\:\\ 0\\.008021731949374625\ \(0\)\
\-\ 0\\.85\\:\\ 0\\.008021731949374625\ \(0\)\
\-\ cytokines\\:\\ 0\\.008021731949374625\ \(0\)\
\-\ economic\\:\\ 0\\.008021731949374625\ \(0\)\
\-\ barriers\\:\\ 0\\.008021731949374625\ \(0\)\
\-\ to\\:\\ 0\\.007990879367956085\ \(0\)\
\-\ it\\:\\ 0\\.007986895569783853\ \(0\)\
\-\ in\\:\\ 0\\.007884771457925769\ \(0\)\
\-\ lobes\\:\\ 0\\.007828819993174555\ \(0\)\
\-\ pulmonary\\:\\ 0\\.007785499927921196\ \(0\)\
\-\ aspergilloma\\:\\ 0\\.007722686136015185\ \(0\)\
\-\ lch\\:\\ 0\\.007722686136015185\ \(0\)\
\-\ mononuclear\\:\\ 0\\.007722686136015185\ \(0\)\
\-\ misdiagnosis\\:\\ 0\\.007722686136015185\ \(0\)\
\-\ atypical\\:\\ 0\\.007699647891080988\ \(0\)\
\-\ have\\:\\ 0\\.007694129223971276\ \(0\)\
\-\ that\\:\\ 0\\.007671417508101993\ \(0\)\
\-\ ii\\:\\ 0\\.007662411037512318\ \(0\)\
\-\ infectious\\:\\ 0\\.007637951907409227\ \(0\)\
\-\ stage\\:\\ 0\\.007578034155776189\ \(0\)\
\-\ lymphadenopathy\\:\\ 0\\.007554542356911462\ \(0\)\
\-\ inflammation\\:\\ 0\\.007554542356911462\ \(0\)\
\-\ time\\:\\ 0\\.007526822953968751\ \(0\)\
\-\ compared\\:\\ 0\\.007519794995219694\ \(0\)\
\-\ etiology\\:\\ 0\\.007519794995219694\ \(0\)\
\-\ features\\:\\ 0\\.007496948588617625\ \(0\)\
\-\ traced\\:\\ 0\\.00749072818246611\ \(0\)\
\-\ mimicked\\:\\ 0\\.00749072818246611\ \(0\)\
\-\ nodules\\:\\ 0\\.007364904086076407\ \(0\)\
\-\ preferentially\\:\\ 0\\.0073012047346553465\ \(0\)\
\-\ clues\\:\\ 0\\.0073012047346553465\ \(0\)\
\-\ blacks\\:\\ 0\\.0073012047346553465\ \(0\)\
\-\ encase\\:\\ 0\\.0073012047346553465\ \(0\)\
\-\ uveitis\\:\\ 0\\.0073012047346553465\ \(0\)\
\-\ prominent\\:\\ 0\\.007291581552110797\ \(0\)\
\-\ cell\\:\\ 0\\.007198255857322723\ \(0\)\
\-\ lymph\\:\\ 0\\.00717160583980176\ \(0\)\
\-\ activation\\:\\ 0\\.00714096494273512\ \(0\)\
\-\ noncalcified\\:\\ 0\\.007002158921295907\ \(0\)\
\-\ beaded\\:\\ 0\\.007002158921295907\ \(0\)\
\-\ 20\\-40\\:\\ 0\\.007002158921295907\ \(0\)\
\-\ lifetime\\:\\ 0\\.007002158921295907\ \(0\)\
\-\ fibroblasts\\:\\ 0\\.007002158921295907\ \(0\)\
\-\ extrathoracic\\:\\ 0\\.007002158921295907\ \(0\)\
\-\ enzyme\\:\\ 0\\.007002158921295907\ \(0\)\
\-\ unknown\\:\\ 0\\.006933221415019765\ \(0\)\
\-\ 4\\.6\\:\\ 0\\.006879723333295508\ \(0\)\
\-\ malignancy\\:\\ 0\\.006865051305200657\ \(0\)\
\-\ skin\\:\\ 0\\.006823552879914716\ \(0\)\
\-\ hrct\\:\\ 0\\.006770200967746832\ \(0\)\
\-\ hallmark\\:\\ 0\\.006770200967746832\ \(0\)\
\-\ 1\\,2\\:\\ 0\\.006770200967746832\ \(0\)\
\-\ recruit\\:\\ 0\\.006770200967746832\ \(0\)\
\-\ centrilobular\\:\\ 0\\.006671125936765206\ \(0\)\
\-\ bronchovascular\\:\\ 0\\.006671125936765206\ \(0\)\
\-\ ago\\:\\ 0\\.006612741831179311\ \(0\)\
\-\ acute\\:\\ 0\\.006579665267483873\ \(0\)\
\-\ since\\:\\ 0\\.006525498174008767\ \(0\)\
\-\ early\\:\\ 0\\.006497211995098623\ \(0\)\
\-\ bilateral\\:\\ 0\\.00646720705607415\ \(0\)\
\-\ upper\\:\\ 0\\.006430604486596835\ \(0\)\
\-\ cts\\:\\ 0\\.006420437728015841\ \(0\)\
\-\ 10mm\\:\\ 0\\.006420437728015841\ \(0\)\
\-\ epidemiology\\:\\ 0\\.006420437728015841\ \(0\)\
\-\ ground\\-glass\\:\\ 0\\.006348719566386994\ \(0\)\
\-\ bronchoalveolar\\:\\ 0\\.006348719566386994\ \(0\)\
\-\ histologically\\:\\ 0\\.006281631706576629\ \(0\)\
\-\ pneumoconiosis\\:\\ 0\\.006218612349179088\ \(0\)\
\-\ bundles\\:\\ 0\\.006218612349179088\ \(0\)\
\-\ a\\:\\ 0\\.006183988593845134\ \(0\)\
\-\ silicosis\\:\\ 0\\.006159196118576231\ \(0\)\
\-\ tight\\:\\ 0\\.006159196118576231\ \(0\)\
\-\ inflamed\\:\\ 0\\.006159196118576231\ \(0\)\
\-\ elsewhere\\:\\ 0\\.006102993185862847\ \(0\)\
\-\ pathogenesis\\:\\ 0\\.006102993185862847\ \(0\)\
\-\ came\\:\\ 0\\.006049673753027555\ \(0\)\
\-\ mechanisms\\:\\ 0\\.006049673753027555\ \(0\)\
\-\ thickening\\:\\ 0\\.006022088502480981\ \(0\)\
\-\ fissures\\:\\ 0\\.005998956326656003\ \(0\)\
\-\ areas\\:\\ 0\\.00597785274687332\ \(0\)\
\-\ followed\\:\\ 0\\.005956082892679359\ \(0\)\
\-\ adenomatous\\:\\ 0\\.005950598722045928\ \(0\)\
\-\ hypercalcemia\\:\\ 0\\.005950598722045928\ \(0\)\
\-\ pneumonitis\\:\\ 0\\.005904391068645893\ \(0\)\
\-\ indications\\:\\ 0\\.005860150305216791\ \(0\)\
\-\ predilection\\:\\ 0\\.005860150305216791\ \(0\)\
\-\ proposed\\:\\ 0\\.005860150305216791\ \(0\)\
\-\ density\\:\\ 0\\.0058453874362992915\ \(0\)\
\-\ is\\:\\ 0\\.0058450184863277094\ \(0\)\
\-\ trapping\\:\\ 0\\.005776945827385672\ \(0\)\
\-\ reticular\\:\\ 0\\.005776945827385672\ \(0\)\
\-\ ppd\\:\\ 0\\.005776945827385672\ \(0\)\
\-\ lymphocytes\\:\\ 0\\.005737714717216393\ \(0\)\
\-\ findings\\:\\ 0\\.005672048656309645\ \(0\)\
\-\ often\\:\\ 0\\.005668344175716533\ \(0\)\
\-\ 1998\\:\\ 0\\.005663433049875285\ \(0\)\
\-\ radiograph\\:\\ 0\\.005658936910439423\ \(0\)\
\-\ radiographs\\:\\ 0\\.00562634270520194\ \(0\)\
\-\ 5mm\\:\\ 0\\.005594107296758162\ \(0\)\
\-\ predominance\\:\\ 0\\.005561104491857351\ \(0\)\
\-\ such\\:\\ 0\\.005553706423785556\ \(0\)\
\-\ image\\:\\ 0\\.0055492498259825385\ \(0\)\
\-\ 2\\.4\\:\\ 0\\.00552911732068609\ \(0\)\
\-\ be\\:\\ 0\\.005479237934901992\ \(0\)\
\-\ united\\:\\ 0\\.0054679525597474896\ \(0\)\
\-\ presents\\:\\ 0\\.005443797179338647\ \(0\)\
\-\ established\\:\\ 0\\.005438668903856953\ \(0\)\
\-\ furthermore\\:\\ 0\\.005438668903856953\ \(0\)\
\-\ selected\\:\\ 0\\.005382465971143569\ \(0\)\
\-\ as\\:\\ 0\\.005374542644050428\ \(0\)\
\-\ \\‚\\Ä\\ô\\:\\ 0\\.0053098269015498046\ \(0\)\
\-\ bands\\:\\ 0\\.005303478541852589\ \(0\)\
\-\ see\\:\\ 0\\.005301906884051535\ \(0\)\
\-\ reasons\\:\\ 0\\.005278429111936725\ \(0\)\
\-\ distortion\\:\\ 0\\.005278429111936725\ \(0\)\
\-\ from\\:\\ 0\\.0052658449611401766\ \(0\)\
\-\ receive\\:\\ 0\\.00523007150732665\ \(0\)\
\-\ usual\\:\\ 0\\.005183863853926615\ \(0\)\
\-\ bronchiectasis\\:\\ 0\\.005183863853926615\ \(0\)\
\-\ infection\\:\\ 0\\.0051642756217729876\ \(0\)\
\-\ ensure\\:\\ 0\\.005161508131243701\ \(0\)\
\-\ detection\\:\\ 0\\.005161508131243701\ \(0\)\
\-\ cutaneous\\:\\ 0\\.005161508131243701\ \(0\)\
\-\ lung\\:\\ 0\\.00514586095683731\ \(0\)\
\-\ estimated\\:\\ 0\\.005139623090497513\ \(0\)\
\-\ non\\-specific\\:\\ 0\\.005139623090497513\ \(0\)\
\-\ discrete\\:\\ 0\\.005118189320016499\ \(0\)\
\-\ organs\\:\\ 0\\.005097188584759202\ \(0\)\
\-\ s\\:\\ 0\\.0050951510750823015\ \(0\)\
\-\ syndrome\\:\\ 0\\.005080886853918174\ \(0\)\
\-\ collagen\\:\\ 0\\.005056418612666393\ \(0\)\
\-\ bronchial\\:\\ 0\\.005036617994193739\ \(0\)\
\-\ carcinoma\\:\\ 0\\.0050351926611556476\ \(0\)\
\-\ all\\:\\ 0\\.005024788959316613\ \(0\)\
\-\ likely\\:\\ 0\\.00501099785017808\ \(0\)\
\-\ stability\\:\\ 0\\.00496098456978373\ \(0\)\
\-\ look\\:\\ 0\\.004942905835156008\ \(0\)\
\-\ an\\:\\ 0\\.004913367419063326\ \(0\)\
\-\ lines\\:\\ 0\\.004890482910387929\ \(0\)\
\-\ emphysema\\:\\ 0\\.004856947710576888\ \(0\)\
\-\ institution\\:\\ 0\\.004840577277138073\ \(0\)\
\-\ septal\\:\\ 0\\.004840577277138073\ \(0\)\
\-\ pericardial\\:\\ 0\\.004777557919740532\ \(0\)\
\-\ eyes\\:\\ 0\\.004777557919740532\ \(0\)\
\-\ patchy\\:\\ 0\\.0047623824525667765\ \(0\)\
\-\ impression\\:\\ 0\\.004747425345028211\ \(0\)\
\-\ topic\\:\\ 0\\.004718141689137675\ \(0\)\
\-\ 46\\:\\ 0\\.004703803516442939\ \(0\)\
\-\ and\\:\\ 0\\.004677988714454742\ \(0\)\
\-\ common\\:\\ 0\\.004649204182861533\ \(0\)\
\-\ suspicion\\:\\ 0\\.004608619323588998\ \(0\)\
\-\ helpful\\:\\ 0\\.004595706101137276\ \(0\)\
\-\ both\\:\\ 0\\.004536798317434764\ \(0\)\
\-\ suggested\\:\\ 0\\.00452142443379617\ \(0\)\
\-\ the\\:\\ 0\\.00445501852995052\ \(0\)\
\-\ order\\:\\ 0\\.004452098680679046\ \(0\)\
\-\ by\\:\\ 0\\.004437227348996491\ \(0\)\
\-\ 32\\:\\ 0\\.004429980802875216\ \(0\)\
\-\ delay\\:\\ 0\\.004408323747882656\ \(0\)\
\-\ destruction\\:\\ 0\\.004387108704606974\ \(0\)\
\-\ hyperplasia\\:\\ 0\\.004376661370039924\ \(0\)\
\-\ parenchymal\\:\\ 0\\.0043663179907746765\ \(0\)\
\-\ erythema\\:\\ 0\\.0043663179907746765\ \(0\)\
\-\ interstitial\\:\\ 0\\.0043459349643834334\ \(0\)\
\-\ women\\:\\ 0\\.004316090779474461\ \(0\)\
\-\ fungal\\:\\ 0\\.004306330134620158\ \(0\)\
\-\ part\\:\\ 0\\.004306330134620158\ \(0\)\
\-\ granulomatous\\:\\ 0\\.0042870795652155454\ \(0\)\
\-\ serum\\:\\ 0\\.0042870795652155454\ \(0\)\
\-\ mediastinum\\:\\ 0\\.004277586339058297\ \(0\)\
\-\ lead\\:\\ 0\\.0042588560838580074\ \(0\)\
\-\ leading\\:\\ 0\\.004249616013777711\ \(0\)\
\-\ versus\\:\\ 0\\.0042223786204367295\ \(0\)\
\-\ dyspnea\\:\\ 0\\.004204608939190056\ \(0\)\
\-\ nature\\:\\ 0\\.004204608939190056\ \(0\)\
\-\ dense\\:\\ 0\\.004195836726460467\ \(0\)\
\-\ 90\\:\\ 0\\.004187137922229161\ \(0\)\
\-\ phase\\:\\ 0\\.00417851130807667\ \(0\)\
\-\ states\\:\\ 0\\.00417851130807667\ \(0\)\
\-\ iii\\:\\ 0\\.004169955695668651\ \(0\)\
\-\ discussion\\:\\ 0\\.004161469925773473\ \(0\)\
\-\ opacity\\:\\ 0\\.004153052867319607\ \(0\)\
\-\ improvement\\:\\ 0\\.00414470341649085\ \(0\)\
\-\ scans\\:\\ 0\\.004136420495857609\ \(0\)\
\-\ 27\\:\\ 0\\.004120050062418795\ \(0\)\
\-\ t\\:\\ 0\\.004111960519339736\ \(0\)\
\-\ was\\:\\ 0\\.004109262046626557\ \(0\)\
\-\ displaced\\:\\ 0\\.004080217563144225\ \(0\)\
\-\ incidence\\:\\ 0\\.004072431002095205\ \(0\)\
\-\ node\\:\\ 0\\.004064702334228762\ \(0\)\
\-\ regions\\:\\ 0\\.004064702334228762\ \(0\)\
\-\ symmetric\\:\\ 0\\.004057030705021255\ \(0\)\
\-\ those\\:\\ 0\\.004041855237847499\ \(0\)\
\-\ reaction\\:\\ 0\\.004034349782573604\ \(0\)\
\-\ can\\:\\ 0\\.004029568300351496\ \(0\)\
\-\ nodes\\:\\ 0\\.004012153187489852\ \(0\)\
\-\ distribution\\:\\ 0\\.003997614474418397\ \(0\)\
\-\ of\\:\\ 0\\.0039964921271659236\ \(0\)\
\-\ thickened\\:\\ 0\\.003983276301723662\ \(0\)\
\-\ marrow\\:\\ 0\\.0039077677948214035\ \(0\)\
\-\ until\\:\\ 0\\.0039011677660494093\ \(0\)\
\-\ may\\:\\ 0\\.0038967325756717754\ \(0\)\
\-\ clinically\\:\\ 0\\.0038946093781146228\ \(0\)\
\-\ smooth\\:\\ 0\\.003888092108869721\ \(0\)\
\-\ absent\\:\\ 0\\.003849823945540494\ \(0\)\
\-\ affected\\:\\ 0\\.0038435806772866357\ \(0\)\
\-\ causing\\:\\ 0\\.0038373746824981697\ \(0\)\
\-\ continued\\:\\ 0\\.0038250727514721793\ \(0\)\
\-\ foci\\:\\ 0\\.0038129147059802965\ \(0\)\
\-\ relatively\\:\\ 0\\.0038008972190768913\ \(0\)\
\-\ suggestive\\:\\ 0\\.003794940176759859\ \(0\)\
\-\ test\\:\\ 0\\.003794940176759859\ \(0\)\
\-\ but\\:\\ 0\\.003788988151836877\ \(0\)\
\-\ collection\\:\\ 0\\.003759897497609847\ \(0\)\
\-\ and\\/or\\:\\ 0\\.003754170204667051\ \(0\)\
\-\ diameter\\:\\ 0\\.003737175258719515\ \(0\)\
\-\ us\\:\\ 0\\.0037259977204905526\ \(0\)\
\-\ outside\\:\\ 0\\.0037259977204905526\ \(0\)\
\-\ increase\\:\\ 0\\.0037259977204905526\ \(0\)\
\-\ nodular\\:\\ 0\\.0037259977204905526\ \(0\)\
\-\ recommended\\:\\ 0\\.0036824520430382033\ \(0\)\
\-\ pneumonia\\:\\ 0\\.003671844797534834\ \(0\)\
\-\ nodule\\:\\ 0\\.0036613446977567634\ \(0\)\
\-\ presenting\\:\\ 0\\.0036203738364876605\ \(0\)\
\-\ attenuation\\:\\ 0\\.0035713316740395413\ \(0\)\
\-\ additional\\:\\ 0\\.0035617949003638226\ \(0\)\
\-\ patient\\:\\ 0\\.0035617128104631517\ \(0\)\
\-\ irregular\\:\\ 0\\.00354297988826027\ \(0\)\
\-\ persistent\\:\\ 0\\.00354297988826027\ \(0\)\
\-\ complications\\:\\ 0\\.003519930140345174\ \(0\)\
\-\ diagnostic\\:\\ 0\\.003519930140345174\ \(0\)\
\-\ use\\:\\ 0\\.003510851470938984\ \(0\)\
\-\ marked\\:\\ 0\\.0034666107075098825\ \(0\)\
\-\ causes\\:\\ 0\\.003457984093357393\ \(0\)\
\-\ rare\\:\\ 0\\.0034494284809493724\ \(0\)\
\-\ process\\:\\ 0\\.0034200264915121774\ \(0\)\
\-\ cough\\:\\ 0\\.003403591350112341\ \(0\)\
\-\ pattern\\:\\ 0\\.0033954702069348007\ \(0\)\
\-\ active\\:\\ 0\\.0033914333046204583\ \(0\)\
\-\ cardiac\\:\\ 0\\.0033834062296787637\ \(0\)\
\-\ 50\\:\\ 0\\.0033794158177170527\ \(0\)\
\-\ effusion\\:\\ 0\\.0033754406654941805\ \(0\)\
\-\ radiographic\\:\\ 0\\.0033714806567450455\ \(0\)\
\-\ lungs\\:\\ 0\\.0033636056112061083\ \(0\)\
\-\ 8\\:\\ 0\\.003321328023128221\ \(0\)\
\-\ \\‚\\Ä\\ú\\:\\ 0\\.0033175685215999584\ \(0\)\
\-\ \\‚\\Ä\\ù\\:\\ 0\\.0032989723004453065\ \(0\)\
\-\ abnormality\\:\\ 0\\.0032770872596991187\ \(0\)\
\-\ laboratory\\:\\ 0\\.0032734841329044345\ \(0\)\
\-\ abnormalities\\:\\ 0\\.0032627490870043834\ \(0\)\
\-\ above\\:\\ 0\\.0032556534892181047\ \(0\)\
\-\ involvement\\:\\ 0\\.0032556534892181047\ \(0\)\
\-\ middle\\:\\ 0\\.0032486059975493117\ \(0\)\
\-\ presence\\:\\ 0\\.0032243093746955605\ \(0\)\
\-\ care\\:\\ 0\\.0032039263483043165\ \(0\)\
\-\ 20\\:\\ 0\\.003193882781868\ \(0\)\
\-\ typically\\:\\ 0\\.0031355777229791814\ \(0\)\
\-\ because\\:\\ 0\\.0031076073976985946\ \(0\)\
\-\ being\\:\\ 0\\.003095413697297878\ \(0\)\
\-\ liver\\:\\ 0\\.0030626003231109394\ \(0\)\
\-\ presentation\\:\\ 0\\.0030596680192214996\ \(0\)\
\-\ enlarged\\:\\ 0\\.003030791133455308\ \(0\)\
\-\ elevated\\:\\ 0\\.0030138423714751177\ \(0\)\
\-\ air\\:\\ 0\\.003005470505771275\ \(0\)\
\-\ cause\\:\\ 0\\.003005470505771275\ \(0\)\
\-\ asymptomatic\\:\\ 0\\.003002694800411733\ \(0\)\
\-\ masses\\:\\ 0\\.003002694800411733\ \(0\)\
\-\ although\\:\\ 0\\.002999926487085867\ \(0\)\
\-\ this\\:\\ 0\\.002997309397029521\ \(0\)\
\-\ cases\\:\\ 0\\.00295926285237124\ \(0\)\
\-\ along\\:\\ 0\\.0029356069406013684\ \(0\)\
\-\ x\\:\\ 0\\.0029304223860160887\ \(0\)\
\-\ vascular\\:\\ 0\\.002912477409484092\ \(0\)\
\-\ follow\\-up\\:\\ 0\\.0028898513424550332\ \(0\)\
\-\ finding\\:\\ 0\\.002862849797337299\ \(0\)\
\-\ several\\:\\ 0\\.0028556058583392805\ \(0\)\
\-\ follow\\:\\ 0\\.002822452673540992\ \(0\)\
\-\ differential\\:\\ 0\\.0028201245627369332\ \(0\)\
\-\ area\\:\\ 0\\.0028085615843391554\ \(0\)\
\-\ medical\\:\\ 0\\.002733170270338882\ \(0\)\
\-\ show\\:\\ 0\\.002726773320677366\ \(0\)\
\-\ some\\:\\ 0\\.0026974306173251136\ \(0\)\
\-\ no\\:\\ 0\\.002683297767267574\ \(0\)\
\-\ there\\:\\ 0\\.0026438992857899975\ \(0\)\
\-\ demonstrated\\:\\ 0\\.002606465678229696\ \(0\)\
\-\ appearance\\:\\ 0\\.002540443426959087\ \(0\)\
\-\ lymphoma\\:\\ 0\\.0025386680191158894\ \(0\)\
\-\ abnormal\\:\\ 0\\.0025333599171672677\ \(0\)\
\-\ chronic\\:\\ 0\\.002502068225475052\ \(0\)\
\-\ she\\:\\ 0\\.0024935406875823\ \(0\)\
\-\ include\\:\\ 0\\.0024918435426510258\ \(0\)\
\-\ scan\\:\\ 0\\.002486768669888751\ \(0\)\
\-\ performed\\:\\ 0\\.0024766926520034503\ \(0\)\
\-\ 4\\:\\ 0\\.0024750227704563883\ \(0\)\
\-\ shows\\:\\ 0\\.002442176403044573\ \(0\)\
\-\ presented\\:\\ 0\\.0024213696829754774\ \(0\)\
\-\ been\\:\\ 0\\.002416626704224523\ \(0\)\
\-\ one\\:\\ 0\\.002407205180156595\ \(0\)\
\-\ at\\:\\ 0\\.002406992001728967\ \(0\)\
\-\ lobe\\:\\ 0\\.0023901510893176033\ \(0\)\
\-\ up\\:\\ 0\\.0023886145021353674\ \(0\)\
\-\ due\\:\\ 0\\.002370350470844948\ \(0\)\
\-\ mild\\:\\ 0\\.0023391408045022213\ \(0\)\
\-\ than\\:\\ 0\\.002327493612181158\ \(0\)\
\-\ symptoms\\:\\ 0\\.002213781161016777\ \(0\)\
\-\ bone\\:\\ 0\\.0022073125586900937\ \(0\)\
\-\ with\\:\\ 0\\.002189267328085255\ \(0\)\
\-\ consistent\\:\\ 0\\.0021780647285147645\ \(0\)\
\-\ noted\\:\\ 0\\.002105427430823902\ \(0\)\
\-\ \\;\\:\\ 0\\.002105427430823902\ \(0\)\
\-\ 3\\:\\ 0\\.002080016140027588\ \(0\)\
\-\ most\\:\\ 0\\.0020507641805905157\ \(0\)\
\-\ other\\:\\ 0\\.002047441318817514\ \(0\)\
\-\ well\\:\\ 0\\.002009439660050573\ \(0\)\
\-\ lower\\:\\ 0\\.001997777618881354\ \(0\)\
\-\ contrast\\:\\ 0\\.0019883323147691324\ \(0\)\
\-\ year\\:\\ 0\\.0019877448425632323\ \(0\)\
\-\ \\'s\\:\\ 0\\.0019584684182609616\ \(0\)\
\-\ right\\:\\ 0\\.0018744941977347541\ \(0\)\
\-\ after\\:\\ 0\\.001837839087951354\ \(0\)\
\-\ female\\:\\ 0\\.0018261541283241514\ \(0\)\
\-\ old\\:\\ 0\\.0018189908458674732\ \(0\)\
\-\ has\\:\\ 0\\.0016680872874160894\ \(0\)\
\-\ \\.\\:\\ 0\\.0015867776010248336\ \(0\)\
\-\ on\\:\\ 0\\.0015049709196786447\ \(0\)\
\-\ normal\\:\\ 0\\.0013925285390843046\ \(0\)\
\-\ not\\:\\ 0\\.0012835952928710347\ \(0\)\
\-\ pain\\:\\ 0\\.0010848317749799737\ \(0\)\
